arrow_back Back to App

FDA Program to Accelerate Vaccine and Drug Approval for Future Pandemics.

This Act establishes a new preparedness program within the FDA to streamline the development and approval of medical countermeasures, such as vaccines and treatments, against emerging pathogens. This initiative aims to enhance public health security by ensuring faster access to approved medical solutions during future health crises. The program is authorized to receive $60 million annually from 2024 through 2028.
Key points
Establishes a dedicated FDA program to speed up the review and approval process for new vaccines and treatments during potential pandemics.
Activities include advancing scientific research, monitoring countermeasure safety, and prioritizing the development of platform vaccine technologies.
Authorizes $60 million per year (FY 2024–2028) to fund these preparedness efforts, focusing on national health security.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_2329
Sponsor: Sen. Hickenlooper, John W. [D-CO]
Process start date: 2023-07-13
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Emerging Pathogen Preparedness Program Authorization Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_2329.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-07-13.

What are the main provisions?

Key points include:

  • Establishes a dedicated FDA program to speed up the review and approval process for new vaccines and treatments during potential pandemics.
  • Activities include advancing scientific research, monitoring countermeasure safety, and prioritizing the development of platform vaccine technologies.
  • Authorizes $60 million per year (FY 2024–2028) to fund these preparedness efforts, focusing on national health security.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Hickenlooper, John W. [D-CO].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health